Skip to main content
. 2019 Oct 28;43(2):398–404. doi: 10.2337/dc18-2361

Figure 2.

Figure 2

Estimated rate ratios of nonsevere hypoglycemic events (total and symptomatic; degludec vs. glargine U100) in the maintenance period of SWITCH 2 (A) and 1 (B) at different PG levels. The solid lines represent the estimated rate ratio (degludec vs. glargine U100) at different PG levels. The dashed lines represent the upper and lower 95% CIs.